Rare Disease RWE Strategy: Synthetic Control Arms, Natural History Studies and Real-World Evidence for Orphan Drug Development
Here’s a conversation I’ve had more times than I can count. A clinical development director at a rare disease biotech
Synthetic Patient Cohorts for Clinical Trial Design
If you’ve ever sat through a trial feasibility meeting where the timeline keeps stretching and the recruitment targets keep shrinking,
Synthetic Patient Cohorts for Clinical Trial Design Read Post »